【レポートの概要（一部）】
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1.1. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Top Winning Strategies
3.3.1. Top Player Positioning, 2018
3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increased Consumption In Low And Middle-Income Countries (Lmics)
3.5.1.2. Rise In Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches For New Beta-Lactam And Beta-Lactamase Inhibitors For Treating Bacterial Infections
3.5.2. Restraints
3.5.2.1. Development of Beta-Lactam Resistance
3.5.2.2. Longer Approval Time By The Regulatory Bodies
3.5.3. Opportunity
3.5.3.1. Discovery of Advanced Prospect Molecules And Novel Combination Therapies To Treat Antibiotic-Resistant Microbial Infections
3.6. Antimicrobial Resistance And Countermeasure Trends
3.6.1. Countermeasure Trends
Chapter 4: Beta-Lactam And Beta Lactamase Inhibitors Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Penicillin
4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Cephalosporin
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Carbapenem
4.4.1. Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Monobactam
4.5.1. Key Market Trends And Growth Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.6. Combination
4.6.1. Key Market Trends And Growth Opportunities
4.6.2. Market Size And Forecast, By Type
4.6.2.1. Penicillin/Beta Lactamase Inhibitors
4.6.2.1.1. Market Size And Forecast
4.6.2.2. Cephalosporins/Beta Lactamase Inhibitors
4.6.2.2.1. Market Size And Forecast
4.6.2.3. Carbapenems/Beta Lactamase Inhibitors
4.6.2.3.1. Market Size And Forecast
4.6.3. Market Size And Forecast, By Region
4.6.4. Market Analysis, By Country
Chapter 5: Beta-Lactam And Beta Lactamase Inhibitors Market, By Disease
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Urinary Tract Infection (Excluding Cuti)
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Respiratory Infection
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.4. Skin Infection
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country
5.5. Complicated Urinary Tract Infection (Cuti)
5.5.1. Market Size And Forecast, By Region
5.5.2. Market Analysis, By Country
5.5.3. Number of Patients, By Country
5.6. Complicated Intra-Abdominal Infections (Ciai)
5.6.1. Market Size And Forecast, By Region
5.6.2. Market Analysis, By Country
5.6.3. Number of Patients, By Country
5.7. Nosocomial Pneumonia
5.7.1. Market Size And Forecast, By Type
5.7.1.1. Hospital Acquired Pneumonia
5.7.1.1.1. Market Size And Forecast
5.7.1.2. Ventilator Associated Pneumonia
5.7.1.2.1. Market Size And Forecast
5.7.1.3. Other Nosocomial Pneumonia
5.7.1.3.1. Market Size And Forecast
5.7.2. Market Size And Forecast, By Region
5.7.3. Market Analysis, By Country
5.7.4. Number of Patients, By Country
5.8. Blood Stream Infection
5.8.1. Market Size And Forecast, By Region
5.8.2. Market Analysis, By Country
5.8.3. Number of Patients, By Country
5.9. Other Diseases
5.9.1. Market Size And Forecast, By Region
5.9.2. Market Analysis, By Country
Chapter 6: Beta-Lactam And Beta Lactamase Inhibitors Market, By Route of Administration
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Oral
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country
6.3. Intravenous
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
6.4. Others
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Analysis, By Country
Chapter 7: Beta-Lactam And Beta-Lactamase Inhibitors Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends And Opportunities
7.2.2. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.2.2.1. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.2. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.3. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.4. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.5. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.6. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.7. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.8. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.9. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.3. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.2.4. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.2.5. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
7.3. Europe
7.3.1. Key Market Trends And Opportunities
7.3.2. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.3.2.1. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.2. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.3. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.4. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.5. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.6. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.7. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.8. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.9. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.10. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.11. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.12. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.13. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.14. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.15. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.16. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.17. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.18. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.3. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.3.4. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.3.5. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
7.4. Asia-Pacific
7.4.1. Key Market Trends And Opportunities
7.4.2. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.4.2.1. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.2. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.3. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.4. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.5. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.6. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.7. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.8. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.9. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.10. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.11. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.12. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.13. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.14. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.15. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.16. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.17. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.18. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.19. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.20. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.21. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.22. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.23. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.24. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.25. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.26. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.27. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.3. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.4.4. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.4.5. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
7.5. Lamea
7.5.1. Key Market Trends And Opportunities
7.5.2. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.5.2.1. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.2. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.3. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.4. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.5. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.6. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.7. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.8. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.9. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.10. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.11. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.12. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.3. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.5.4. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.5.5. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Allergan Plc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments
8.3. F. Hoffmann-La Roche Ltd.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Glaxosmithkline Plc
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Merck & Co. Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Mylan N.V.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Novartis International Ag (Sandoz)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Pfizer Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments
8.9. Sanofi
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
【レポート販売概要】
■ タイトル：ベータラクタム及びベータラクタマーゼ阻害剤の世界市場：薬物クラス別、疾患別、投与経路別■ 英文：Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028
■ 発行日：2019年8月
■ 調査会社：Allied Market Research
■ 商品コード：AMR9NV046
■ 調査対象地域：グローバル
- グローバル医学出版市場調査レポート：Global Medical Publishing Market 2014-2018TechNavio's analysts forecast the Global Medical Publishing market to decline at a CAGR of 0.56 percent over the period 2013-2018. One of the major challenges faced by this market is the uncertainty in macroeconomic conditions. The Global Medical Publishing market has also been witnessing the emergence of the digital delivery of journals and books. Despite the declining growth rate, one of the key …
- 自動車パワートレインの世界市場：FWD、RWD、AWD、ガソリン車/ディーゼル車、乗用車/商用車用パワートレイン等The powertrain is a system of motorized parts of a vehicle that produces energy, which is further transformed so as to drive the vehicle. It generally consists of engine, transmission, driveshaft, axles, differential, and clutch/torque converter. The powertrain of any vehicle creates energy initially in the engine, and this energy is transferred to the transmission. The transmission takes the powe …
- クッシング症候群治療薬の世界市場機会分析OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 Summary GlobalData estimates that the 2013 sales for the Cushing’s syndrome (CS) therapeutic market was approximately $179m across the 6MM covered in this report. Pharmaceutical and biotechnology companies that are investing their attention, time, and financial resources in the CS field, have adopted a myriad of r …
- 農機具の世界市場：製品別、地域別Global Farm Equipment Market: About this market Technavio’s farm equipment market analysis considers sales from implement, combines, sprayer, and baler products. Our study also finds the sales of farm equipment in APAC, Europe, MEA, North America, and South America. In 2019, the implement segment had a significant market share, and this trend is expected to continue over the forecast period. Facto …
- 世界の手工具市場（～2019）This industry report offers the most up-to-date market data on the actual market situation, trends and future outlook for non-power-driven hand tools in the world. The research includes historic market data from 2008 to 2014 and forecasts until 2019 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for k …
- 次世代がん診断技術の世界市場：先進PCR技術、CTC検査、FISH検査、マイクロアレイ、次世代シークエンシング技術Next-generation cancer diagnostics – our new study reveals trends, R&D progress, and predicted revenues Where is the next-generation cancer diagnostics market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2025, assessing data, trends, opportunities and business prospects there. Discover How to Stay A …
- 焼却装置の世界市場2015-2019About incinerators Incineration refers to the combustion of organic and harmful waste products. Apart from being effective waste management tools, incinerators also generate heat and electricity. Incinerators reduce the mass of disposable waste by 70% and volume by 90%. Incinerators used in the municipal and industrial sectors include moving grates, rotary kilns, static hearths, static furnaces, m …
- 世界の艦艇及び水上戦闘艦艇市場（2014-2024）：地域別分析Synopsis This report offers detailed analysis of the global Naval Vessels and Surface Combatants market over the next ten years, and provides extensive market size forecasts by country and sub sector. It covers the key technological and market trends in the Naval Vessels and Surface Combatants market. Summary "The Global Naval Vessels and Surface Combatants Market 2014-2024 - Country Analysis: Mar …
- ウイスキーの世界市場2016-2020In 2015, the global whiskey market was the third largest segment and also the fastest growing segment in the global spirits market and is expected to register a CAGR of more than 5% between 2016 and 2020. The demand for premium whiskey is on the rise, especially in major markets such as the UK and the US, and is one of the key drivers of the global whiskey market. Balblair Highland Single Malt Sco …
- Global LTE Industry Landscape: Adoption, Applications, Deployments and Subscriptions by Region, Country, Spectrum and Operator 2011 – 2015While LTE adoption is moving at a much quicker pace than initial analyst expectations, a number of hurdles still exist that undermine the early adoption of LTE by many countries. Firstly the limitation of the frequency spectrum presents a major setback for many network operators, as majority of the spectrum bands suitable for LTE are yet to be fragmented in many regions. The 800 MHz 'digital divid …
- 電力用変圧器の世界市場動向および予測Power transformer market is projected to reach USD 29.91 Billion by 2020, from an estimated USD 20.71 Billion in 2015, at a CAGR of 7.6% from 2015 to 2020. Governments worldwide, due to the rapid increase in electricity demand, are not only focusing on raising generation capacities but also emphasizing on improving T&D infrastructure. The global electricity demand is projected to grow at an annual …
- 整形外科用装具および支持具の世界市場予測The increasing number of accidents and rising number of cases of osteoarthritis, osteoporosis, and other bone disorders has led to increased research activities for treatments that help heal bone injuries. In this report, the global orthopedic braces & supports market has been analysed and segmented based on type, end-user, and region. This market has also been analyzed with an explicit focus on t …
- Ovarian Cancer：グローバル臨床試験レビューH2, 2013Ovarian Cancer Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H2, 2013" provides data on the Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per …
- 軍用航空機MRO（整備・修理・オーバーホール）の世界市場：ラインメンテナンスMRO、エアフレームMRO、エンジンMRO、部品MROAbout Military Aviation MRO MRO plays an important role in sustaining the life of an aircraft. It is an umbrella term for all the services that assure the safety and airworthiness of an aircraft. MRO activities include routine check-up of the aircraft and complete overhaul of the engine. Military aviation MRO is defined as the maintenance, repair, and overhaul of military aircrafts such as fighter …
- 腸炎(Enteritis)：世界の治験レビュー（2015年上半期版）Enteritis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Enteritis Global Clinical Trials Review, H1, 2015" provides data on the Enteritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Enteritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial c …
